China
Africa
Explore chapters and articles related to this topic
Polymorphous Light Eruption
Published in Henry W. Lim, Nicholas A. Soter, Clinical Photomedicine, 2018
The familial photosensitivity rash with autosomal dominant inheritance that is common among Native Americans (16–18) has been considered a unique variant of polymorphous light eruption. However, there are many differences, such as primary eczematous and prurigo lesions, cheilitis, and pterygia formation that help to differentiate this condition as a separate entity (17,19,20). This peculiar rash closely resembles actinic prurigo (21,22), a disease that is clearly different from polymorphous light eruption.
Polymorphous Light Eruption, Hydroa Vacciniforme, and Actinic Prurigo
Published in Henry W. Lim, Herbert Hönigsmann, John L. M. Hawk, Photodermatology, 2007
Herbert Hönigsmann, Maria Teresa Hojyo-Tomoka
Actinic prurigo (AP) is a chronic photodermatosis of unknown etiology, frequent in Latin American mestizos (Caucasians and indigenous offspring) and in Amerindians living at high altitudes. A possible pathogenetic mechanism could consist of a delayed hypersensitivity reaction to UV-induced autoantigens in subjects with genetic susceptibility. The AP has been originally classified as a variant of PLE (67,68); however, there is now sufficient clinical, histologic, epidemiological, and immunogenetic data that confirm that AP and PLE are two different diseases (69).
Thalidomide
Published in Sarah H. Wakelin, Howard I. Maibach, Clive B. Archer, Handbook of Systemic Drug Treatment in Dermatology, 2015
Elaine Agius, Robert P.E. Sarkany
Thalidomide is only licensed in Europe for the treatment of multiple myeloma. It is widely used to treat leprosy reactions (erythema nodosum leprosum) and licensed for this indication in the USA. It has also been reported to be of benefit in a range of inflammatory skin diseases including: Actinic prurigo.Cutaneous lupus erythematosus.Erythema nodosom leprosum.Nodular prurigo.Pyoderma gangrenosum.Severe apthous stomatitis and Behçet’s syndrome.Graft-versus-host disease.Cutaneous sarcoidosis.Erythema multiforme.Kaposi’s sarcoma.Lichen planus.Uraemic pruritus.Systemic mastocytosis.
The emerging role of dupilumab in dermatological indications
Published in Expert Opinion on Biological Therapy, 2021
Maddalena Napolitano, Adriana Di Guida, Mariateresa Nocerino, Gabriella Fabbrocini, Cataldo Patruno
PDare a broad group of skin conditions probably associated with a Th2-mediated inflammation [125]. In literature, 2 cases of chronic actinic dermatitis and 1 of actinic prurigo have been treated with dupilumab [126–128]. PEO is a rare disease characterized by higher levels of IL-4, IL-13, and IL-22 in serum [129]. Three patients successfully treated with dupilumab have been reported [130,131]. EAE is another rare chronic skin disease for which there is no gold standard therapy [132]. In literature, there are 2 case reports of therapeutic success with dupilumab [133,134]. Finally, a single case of EBP successfully treated with dupilumab has been described [135].
Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis
Published in Expert Review of Clinical Pharmacology, 2021
Kyle A. Williams, Youkyung S. Roh, Isabelle Brown, Nishadh Sutaria, Pegah Bakhshi, Justin Choi, Sylvie Gabriel, Rajeev Chavda, Shawn G. Kwatra
Actinic prurigo is a rare, intensely itchy photodermatosis that presents with acute eruptions of pruritic papules or nodules in sun-exposed areas, often accompanied by cheilitis and conjunctivitis [51]. Compared to PN, actinic prurigo more commonly affects young girls, who present with extreme photosensitivity to UVA and UVB.